Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 14/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2770276 | 0.86 | MAPT (0.57) | EPHX2SMN1; SMN2MEN1ALDH1A1GAA | |
| SCHEMBL2771187 | 0.85 | SMN1; SMN2 (0.61) | EPHX2SMN1; SMN2MEN1ALDH1A1GAA | |
| SCHEMBL2769319 | 0.85 | ALDH1A1 (0.55) | EPHX2SMN1; SMN2MEN1ALDH1A1GAA | |
| SCHEMBL2784411 | 0.83 | EPHX2 (0.56) | EPHX2SMN1; SMN2MEN1ALDH1A1GAA | |
| SCHEMBL2770755 | 0.80 | EPHX2 (0.67) | EPHX2SMN1; SMN2ALDH1A1MAPTKMT2A | |
| SCHEMBL2768326 | 0.80 | HIF1A (0.60) | EPHX2SMN1; SMN2MEN1ALDH1A1GAA | |
| SCHEMBL2768846 | 0.79 | HIF1A (0.64) | SMN1; SMN2MEN1ALDH1A1GAAMAPT | |
| SCHEMBL2768457 | 0.78 | ALDH1A1 (0.52) | EPHX2SMN1; SMN2MEN1ALDH1A1GAA | |
| SCHEMBL2768332 | 0.78 | POLB (0.56) | SMN1; SMN2MEN1ALDH1A1GAAMAPT | |
| SCHEMBL2768623 | 0.77 | MAPT (0.59) | SMN1; SMN2MEN1ALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1881967-B1 | SUBSTITUTED BENZO(D)ISOXAZOL-3-YL AMINE COMPOUNDS AS ANALGESICS | GRUENENTHAL GMBH (DE) | 2010-04-28 | — | — | EP | claimed |
| US-20080176915-A1 | Substituted Benzo[d]isoxazol-3-yl Amine Compounds as Analgesics | GRUENENTHAL GMBH (DE) | 2008-07-24 | — | — | US | claimed |
| US-7696238-B2 | Substituted benzo[d]isoxazol-3-yl amine compounds as analgesics | GRUENENTHAL GMBH (DE) | 2010-04-13 | — | — | US | disclosed |
| US-20080176915-A1 | Substituted Benzo[d]isoxazol-3-yl Amine Compounds as Analgesics | GRUENENTHAL GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176915-A1 | Substituted Benzo[d]isoxazol-3-yl Amine Compounds as Analgesics | KCNQ1, KCNQ2, KCNQ3 | EPHX2 3694/4885SMN1; SMN2 1349/4885MEN1 3801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.